We are live on ! Find out more
BIIB icon

Biogen
BIIB

1,014 hedge funds and large institutions have $59B invested in Biogen in 2017 Q3 according to their latest regulatory filings, with 99 funds opening new positions, 380 increasing their positions, 356 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more funds holding in top 10

Funds holding in top 10: 23 → 38 (+15)

46% more first-time investments, than exits

New positions opened: 99 | Existing positions closed: 68

16% more capital invested

Capital invested by funds: $50.9B → $59B (+$8.14B)

2% more funds holding

Funds holding: 992 → 1,014 (+22)

1.38% more ownership

Funds ownership: 87.77% → 89.15% (+1.4%)

7% more repeat investments, than reductions

Existing positions increased: 380 | Existing positions reduced: 356

22% less call options, than puts

Call options by funds: $974M | Put options by funds: $1.24B

Holders
1,014
Holders Change
+22
Holders Change %
+2.22%
% of All Funds
25.28%
Holding in Top 10
38
Holding in Top 10 Change
+15
Holding in Top 10 Change %
+65.22%
% of All Funds
0.95%
New
99
Increased
380
Reduced
356
Closed
68
Calls
$974M
Puts
$1.24B
Net Calls
-$269M
Net Calls Change
-$87M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$513M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$310M
3
Ameriprise
Ameriprise
Minnesota
+$178M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$167M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$133M

Top Sellers

1
BlackRock
BlackRock
New York
-$344M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$206M
3
Renaissance Technologies
Renaissance Technologies
New York
-$190M
4
SIG
Senator Investment Group
New York
-$136M
5
Citadel Advisors
Citadel Advisors
Florida
-$119M
Name Holding Trade Value Shares
Change 		Change in
Stake
WJA
426
Williams Jones & Associates
New York
$3.29M +$1.31M +4,431 +73%
KAM
427
Kazazian Asset Management
Florida
$3.29M +$1.33M +4,500 +75%
CBT
428
Central Bank & Trust
Kentucky
$3.25M +$193K +653 +7%
CI
429
Cigna Investments
Connecticut
$3.2M -$380K -1,283 -11%
MLIC
430
Mandatum Life Insurance Company
Finland
$3.19M – – –
FBC
431
Fairfield, Bush & Co
Connecticut
$3.13M – – –
FIM
432
Fernwood Investment Management
Massachusetts
$3.1M +$29.6K +100 +1%
SCM
433
Sterling Capital Management
North Carolina
$3.08M +$2.58M +8,707 +777%
MAM
434
Meeder Asset Management
Ohio
$3.05M +$1.13M +3,826 +65%
Fayez Sarofim & Co
435
Fayez Sarofim & Co
Texas
$3.04M – – –
LBC
436
Lawrence B. Cohen
$3.03M +$25.2K +85 +0.9%
BRA
437
Bender Robert & Associates
California
$3.01M +$78.8K +266 +3%
LTFS
438
Ladenburg Thalmann Financial Services
Florida
$2.99M +$161K +544 +6%
FMT
439
First Mercantile Trust
Tennessee
$2.97M +$1.12M +3,781 +66%
PA
440
Pinnacle Associates
New York
$2.9M -$18.7K -63 -0.7%
MM
441
Meridian Management
Arkansas
$2.9M – – –
KC
442
Kepos Capital
New York
$2.9M +$2.74M +9,252 New
FAAS
443
First Allied Advisory Services
California
$2.86M -$129K -437 -5%
ARMC
444
American Research & Management Company
Massachusetts
$2.83M +$25.2K +85 +0.9%
NP
445
NS Partners
United Kingdom
$2.83M +$914K +3,086 +52%
ECM
446
Estabrook Capital Management
New York
$2.82M – – –
GC
447
Gruss & Co
Florida
$2.82M +$1.48M +5,000 +125%
SC
448
Scotia Capital
Ontario, Canada
$2.8M +$2.65M +8,952 New
IUHSA
449
Itau Unibanco Holding S.A.
Brazil
$2.78M +$699K +2,361 +527%
SWP
450
Stratos Wealth Partners
Ohio
$2.78M -$61.9K -209 -2%
16 17
18
19 20

BIIB Hedge Fund Activity: Q3 2017 in Review

1,014 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2017, worth a combined $59B — up 16% from $50.9B a quarter earlier.

Buyers outnumbered sellers: 99 funds opened new BIIB positions and 68 closed out — a net gain of 31 holders — while 380 added to existing stakes and 356 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $513M. The largest seller was BlackRock, cutting an estimated $344M.

  • 1,014 institutional investors held Biogen (BIIB) as of Q3 2017, up from 992 in Q2 2017.
  • Funds reported $59B of Biogen stock for Q3 2017, up 16% quarter-over-quarter.
  • 99 funds opened new Biogen positions in Q3 2017 and 68 closed out, a net change of +31 holders.
  • The largest Biogen buyer in Q3 2017 was T. Rowe Price Associates, an estimated $513M added.
  • The largest Biogen seller in Q3 2017 was BlackRock, an estimated $344M sold.

Based on aggregated 13F filings for Q3 2017.